Focusing on PPM1D, MDM2, MDM4 and USP7, for all of which pharmacological inhibitors are in preclinical testing or clinical trials, we showed that neuroblastoma cell lines have preferential dependency for all four genes in TP53 wild-type cell lines (Figure 2D). Here, MDM2 is linked to neuroblastoma.